It is possible to hypothesize that the genetic background and the transcriptional heterogeneity at baseline of the melanoma cell lines used in the different studies to investigate mechanisms underlying acquired resistance to vemurafenib might be responsible for the diverse modulation of IL-8 and MMP-2 expression observed in the drug-resistant sublines. This evidence concerns the gene CXCL8 and melanoma.